SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Houston-based Moleculin Biotech, Inc., currently trading at $0.80 and showing a market capitalization of $2.4 million, has entered into an agreement with an investor to modify certain terms of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

With rapid innovations in biotechnology, companies are developing improved therapies and diagnostic tools addressing chronic diseases and improving patient outcomes. Moreover, the inclusion of modern ...

Trading Symbol: VNTAD until mid-February when the ... opportunities that may have been unavailable to us as Ventana Biotech, Inc. more easily." "These actions align our corporate identity with ...

When Edward J. Minskoff listed his apartment in a storied Park Avenue co-op in 2022, the price tag was $17.7 million. The apartment, in a white-glove building where the real-estate investor had ...

Shares of Trinity Biotech (NASDAQ:TRIB) traded sharply higher on Tuesday after the Irish MedTech reported encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

(RTTNews) - Sartorius Stedim Biotech reported preliminary fiscal 2024 net profit of 175.1 million euros, down 43.6% from last year. Earnings per share was 1.81 euros compared to 3.37 euros.